Biochemistry of uridine in plasma

Clinica Chimica Acta

Volumn 412, Issue 19-20, 2011, Pages 1712-1724

  Yamamoto, Tetsuya ^a   Koyama, Hidenori ^a   Kurajoh, Masafumi ^a   Shoji, Takuhito ^a   Tsutsumi, Zenta ^a   Moriwaki, Yuji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

ATP; Nucleoside transport; Purine; Pyrimidine; Uridine

Indexed keywords

ACETYL COENZYME A; ADENINE NUCLEOTIDE; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; AMINO ACID; ANTIRETROVIRUS AGENT; BUCLADESINE; FLUOROURACIL; FRUCTOSE; GLUCOSE; INOSINE; LAMIVUDINE; NUCLEOSIDE TRANSPORTER; OCTREOTIDE; PHOSPHORIBOSYL PYROPHOSPHATE; PURINE; PYRIMIDINE; URACIL; UREA; URIDINE; URIDINE DIPHOSPHATE; URIDINE DIPHOSPHATE GLUCOSE; XYLITOL; ZIDOVUDINE;

ACROMEGALY; BIOCHEMISTRY; BLOOD LEVEL; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CORNEA; DRUG HALF LIFE; FOOD COMPOSITION; GENITAL SYSTEM; GIGANTISM; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTESTINE ABSORPTION; LIVER; NONHUMAN; NUCLEIC ACID METABOLISM; NUCLEIC ACID SYNTHESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; REVIEW; UREA CYCLE; URIDINE BLOOD LEVEL;

HUMANS; URIDINE;

EID: 79960620585     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.006     Document Type: Review

References (126)

1. Macdonald G., Assef R., Guiffre A., Lo E. Vasoconstrictor effects of uridine and its nucleotides and their inhibition by adenosine. Clin Exp Pharmacol Physiol 1984, 11(4):381-384.
2. Siggins G.R., Gruol D.L., Padjen A.L., Formans D.S. lontophoresis Transmitter Mechanisms Mammalian Central Nervous System 1978, 453-455. Elsevier. R.W. Ryall, J.S. Kelley (Eds.).
3. van Groeningen C.J., Leyva A., Kraal I., Peters G.J., Pinedo H.M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 1986, 70(6):745-750.
4. Morris D.J. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994, 10(4):281-291.
5. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of ethanol and fructose on plasma uridine and purine bases. Metabolism 1997, 46(5):544-547.
6. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of beer on the plasma concentrations of uridine and purine bases. Metabolism 2002, 51(10):1317-1323.
7. Yamamoto T., Moriwaki Y., Ka T., et al. Effect of purine-free low-malt liquor (happo-shu) on the plasma concentrations and urinary excretion of purine bases and uridine-comparison between purine-free and regular happo-shu. Horm Metab Res 2004, 36(4):231-237.
8. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Yamakita J., Higashino K. Effect of muscular exercise on the concentration of uridine and purine bases in plasma-adenosine triphosphate consumption-induced pyrimidine degradation. Metabolism 1997, 46(11):1339-1342.
9. Ohno M., Ka T., Inokuchi T., et al. Effects of exercise and grape juice ingestion in combination on plasma concentrations of purine bases and uridine. Clin Chim Acta 2008, 388(1-2):167-172.
10. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effects of fructose and xylitol on the urinary excretion of adenosine, uridine, and purine bases. Metabolism 1999, 48(4):520-524.
11. Kobayashi T., Inokuchi T., Yamamoto A., et al. Effects of sucrose on plasma concentrations and urinary excretion of purine bases. Metabolism 2007, 56(4):439-443.
12. Yamamoto T., Moriwaki Y., Takahashi S., et al. Xylitol-induced increase in the plasma concentration and urinary excretion of uridine and purine bases. Metabolism 1998, 47(6):739-743.
13. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of glucose on the plasma concentration and urinary excretion of uridine and purine bases. Metabolism 1999, 48(3):338-341.
14. Yamamoto T., Moriwaki Y., Cheng J., et al. Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism 2002, 51(4):438-442.
15. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Ka T., Hada T. Effect of octreotide acetate on the plasma concentration and urinary excretion of uridine and purine bases. Endocr J 2002, 49(2):139-144.
16. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Yamakita J., Higashino K. Is the plasma uridine level a marker of the overproduction of uric acid?. Metabolism 1997, 46(7):801-804.
17. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Yamakita J., Higashino K. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma. Metabolism 1997, 46(12):1473-1476.
18. Ka T., Inokuchi T., Tamada D., et al. Relationship between plasma uridine and urinary urea excretion. Metabolism 2010, 59(3):441-445.
19. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of amino acids on the plasma concentration and urinary excretion of uric acid and uridine. Metabolism 1999, 48(8):1023-1027.
20. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of branched-chain amino acids on the plasma concentration of uridine does not occur via the action of glucagon or insulin. Metabolism 2000, 49(1):97-100.
21. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of glucagon on the plasma concentration of uridine. Metabolism 1998, 47(6):695-698.
22. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of bucladesine sodium on the plasma concentrations and urinary excretion of purine bases and uridine. Metabolism 1998, 47(8):1005-1008.
23. Ronquist G., Niklasson F. Uridine, xanthine, and urate contents in human seminal plasma. Arch Androl 1984, 13(1):63-70.
24. van Groeningen C.J., Peters G.J., Nadal J.C., Laurensse E., Pinedo H.M. Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 1991, 83(6):437-441.
25. Gerrits G.P., Monnens L.A., De Abreu R.A., Schröder C.H., Trijbels J.M., Gabreëls F.J. Disturbances of cerebral purine and pyrimidine metabolism in young children with chronic renal failure. Nephron 1991, 58(3):310-314.
26. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994, 140(1):1-22.
27. Gasser T., Moyer J.D., Handschumacher R.E. Novel single-pass exchange of circulating uridine in rat liver. Science 14 1981, 213(4509):777-778.
28. Harley E.H., Berman P. Diagnostic and therapeutic approaches in pyrimidine 5'-nucleotidase deficiency. Adv Exp Med Biol 1984, 165 Pt A:103-108.
29. Ronquist G., Stegmayr B., Niklasson F. Sperm motility and interactions among seminal uridine, xanthine, urate, and ATPase in fertile and infertile men. Arch Androl 1985, 15(1):21-27.
30. Rosales C., O'Brien V., Kornberg L., Juliano R. Signal transduction by cell adhesion receptors. Biochim Biophys Acta 1995, 1242(1):77-98.
31. Nishida T., Nakamura M., Mishima H., Otori T. Hyaluronan stimulates corneal epithelial migration. Exp Eye Res 1991, 53(6):753-758.
32. Oh J.Y., In Y.S., Kim M.K., et al. Protective effect of uridine on cornea in a rabbit dry eye model. Invest Ophthalmol Vis Sci 2007, 48(3):1102-1109.
33. Jumblatt J.E., Jumblatt M.M. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res 1998, 67(3):341-346.
34. Choi J.Y., Namkung W., Shin J.H., Yoon J.H. Uridine-5'-triphosphate and adenosine triphosphate gammaS induce mucin secretion via Ca2+-dependent pathways in human nasal epithelial cells. Acta Otolaryngol 2003, 123(9):1080-1086.
35. Merten M.D., Saleh A., Kammouni W., Marchand S., Figarella C. Characterization of two distinct P2Y receptors in human tracheal gland cells. Eur J Biochem 15 1998, 251(1-2):19-24.
36. Geiger A., Yamasaki S. Cytidine and uridine requirement of the brain. J Neurochem 1956, 1(2):93-100.
37. Choi J.W., Shin C.Y., Choi M.S., et al. Uridine protects cortical neurons from glucose deprivation-induced death: possible role of uridine phosphorylase. J Neurotrauma 2008, 25(6):695-707.
38. Connolly G.P., Simmonds H.A., Duley J.A. Pyrimidines and CNS regulation. Trends Pharmacol Sci 1996, 17(3):106-107.
39. Page T., Yu A., Fontanesi J., Nyhan W.L. Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci U S A 14 1997, 94(21):11601-11606.
40. Agnati L.F., Fuxe K., Ruggeri M., et al. Effects of chronic treatment with uridine on striatal dopamine release and dopamine related behaviours in the absence or the presence of chronic treatment with haloperidol. Neurochem Int 1989, 15(1):107-113.
41. Kimura T., Kuze J., Watanabe K., Kondo S., Ho I.K., Yamamoto I. N3-phenacyluridine, a novel hypnotic compound, interacts with the benzodiazepine receptor. Eur J Pharmacol 1996, 311(2-3):265-269.
42. Peters G.J., van Groeningen C.J., Laurensse E.J., Lankelma J., Leyva A., Pinedo H.M. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 1987, 20(2):101-108.
43. van Groeningen C.J., Leyva A., Kraal I., Peters G.J., Pinedo H.M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 1986, 70(6):745-750.
44. Peters G.J., van Groeningen C.J., Laurensse E., et al. Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharm Res 1987, 4(2):113-119.
45. Hasnain Q., Macdonald G. Metabolic studies of uridine in rats with DOCA-salt hypertension and on high sodium diet. Clin Exp Pharmacol Physiol 1993, 20(5):384-387.
46. Seifert R., Schultz G. Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. Trends Pharmacol Sci 1989, 10(9):365-369.
47. Aussedat J. Effect of uridine supply on glycogen resynthesis after ischaemia in the isolated perfused rat heart. Cardiovasc Res 1983, 17(3):145-151.
48. Buse M.G. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 2006, 290(1):E1-E8.
49. Copeland R.J., Bullen J.W., Hart G.W. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab 2008, 295(1):E17-E28.
50. Hawkins M., Angelov I., Liu R., Barzilai N., Rossetti L. The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem 1997, 272(8):4889-4895.
51. Hamada T., Mizuta E., Yanagihara K., et al. Plasma levels of uridine correlate with blood pressure and indicators of myogenic purine degradation and insulin resistance in hypertensive patients. Circ J 2007, 71(3):354-356.
52. Yamamoto T., Inokuchi T., Ka T., et al. Relationship between plasma uridine and insulin resistance in patients with non-insulin-dependent diabetes mellitus. Nucleosides Nucleotides Nucleic Acids 2010, 29(4-6):504-508.
53. Krenisky T.A., Mellors J.W., Barclay R.K. Pyrimodine nucleosidases. Their classification and relationship to uric acid ribonucleoside phosphorylase. J Biol Chem 1965, 240:1281-1286.
54. Krenisky T.A., Barclay M., Jacquez J.A. Specificity of mouse uridine phosphorylase. Chromatography, purification, and properties. J Biol Chem 1964, 239:805-812.
55. Niedzwicki J.G., el Kouni M.H., Chu S.H., Cha S. Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase. Biochem Pharmacol 1981, 30(15):2097-2101.
56. Niedzwicki J.G., Chu S.H., el Kouni M.H., Rowe E.C., Cha S. 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem Pharmacol 1982, 31(10):1857-1861.
57. Houghton J.A., Houghton P.J., Wooten R.S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979, 39(7 Pt 1):2406-2413.
58. Geoffroy F.J., Allegra C.J., Sinha B., Grem J.L. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res 1994, 6(12):581-591.
59. Klubes P., Cerna I. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 1983, 43(7):3182-3186.
60. Klubes P., Cerna I., Meldon M.A. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 1982, 8(1):17-21.
61. Martin D.S., Stolfi R.L., Sawyer R.C., Spiegelman S., Young C.W. High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res 1982, 42(10):3964-3970.
62. Martin D.S., Stolfi R.L., Sawyer R.C., Spiegelman S., Young C.W. Improved therapeutic index with sequential N-phosphonacetyl-l-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue. Cancer Res 1983, 43(10):4653-4661.
63. Peters G.J., van Dijk J., van Groeningen C., et al. Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine. Adv Exp Med Biol 1986, 195 Pt B:121-128.
64. Martin D.S., Stolfi R.L., Sawyer R.C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 1989, 24(1):9-14.
65. Domingo P., Torres-Torronteras J., Pomar V., et al. Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. PLoS One 2010, 5(11):e13896.
66. Calmy A., Bloch M., Wand H., et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010, 11(8):493-501.
67. Sutinen J., Walker U.A., Sevastianova K., et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007, 12(1):97-105.
68. McComsey G.A., O'Riordan M., Setzer B., Lebrecht D., Baron E., Walker U.A. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2008, 62(8):1031-1037.
69. Walker U.A., Venhoff N., Koch E.C., Olschewski M., Schneider J., Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003, 8(5):463-470.
70. Smoleński R.T., de Jong J.W., Janssen M., et al. Formation and breakdown of uridine in ischemic hearts of rats and humans. J Mol Cell Cardiol 1993, 25(1):67-74.
71. Swain J.L., Sabina R.L., McHale P.A., Greenfield J.C., Holmes E.W. Prolonged myocardial nucleotide depletion after brief ischemia in the open-chest dog. Am J Physiol 1982, 242(5):H818-H826.
72. Harkness R.A. Hypoxanthine, xanthine and uridine in body fluids, indicators of ATP depletion. J Chromatogr 29 1988, 429:255-278.
73. Yamamoto T., Moriwaki Y., Takahashi S. Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin Chim Acta 2005, 356(1-2):35-57.
74. Ugarte G., Iturriaga H. Metabolic pathways of alcohol in the liver. Front Gastrointest Res 1976, 2:150-193.
75. Winkler K., Lundquist F., Tygstrup N. The hepatic metabolism of ethanol in patients with cirrhosis of the liver. Scand J Clin Lab Invest 1969, 23(1):59-69.
76. Puig J.G., Fox I.H. Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate. J Clin Invest 1984, 74(3):936-941.
77. Masson S., Desmoulin F., Sciaky M., Cozzone P.J. The effects of ethanol concentration on glycero-3-phosphate accumulation in the perfused rat liver. A reassessment of ethanol-induced inhibition of glycolysis using 31P-NMR spectroscopy and HPLC. Eur J Biochem 1992, 205(1):187-194.
78. Yuki T., Thurman R.G. The swift increase in alcohol metabolism. Time course for the increase in hepatic oxygen uptake and the involvement of glycolysis. Biochem J 1980, 186(1):119-126.
79. Beauvieux M.C., Tissier P., Couzigou P., Gin H., Canioni P., Gallis J.L. Ethanol perfusion increases the yield of oxidative phosphorylation in isolated liver of fed rats. Biochim Biophys Acta 2002, 1570(2):135-140.
80. Topping D.L., Mayes P.A. The concentration of fructose, glucose and lactate in the splanchnic blood vessels of rats absorbing fructose. Nutr Metab 1971, 13(6):331-338.
81. Mendeloff A.I., Weichselbaum T.E. Role of the human liver in the assimilation of intravenously administered fructose. Metabolism 1953, 2(5):450-458.
82. Perheentupa J., Raivio K. Fructose-induced hyperuricaemia. Lancet 1967, 2(7515):528-531.
83. Narins R.G., Weisberg J.S., Myers A.R. Effects of carbohydrates on uric acid metabolism. Metabolism 1974, 23(5):455-465.
84. Mäenpää P.H., Raivio K.O., Kekomäki M.P. Liver adenine nucleotides: fructose-induced depletion and its effect on protein synthesis. Science 1968, 161(847):1253-1254.
85. Woods H.F., Eggleston L.V., Krebs H.A. The cause of hepatic accumulation of fructose 1-phosphate on fructose loading. Biochem J 1970, 119(3):501-510.
86. Bässler K.H., Prellwitz W. Insulin und der Verteilungsraum von Xylit bei eviscerierten Ratten. Klin Wochenschr 1964, 42:94-95.
87. Bässler K.H., Prellwitz W., Unbehaun V., Lang K. Xylitstoffwechsel beim Menschen. Klin Wochenschr 1962, 40:791.
88. Prellwitz W., Bassler K.H. Die Vertraglichkeit von Xylit beim Diabetiker. Klin Wochenschr 1963, 41:196-199.
89. Yamamoto T., Moriwaki Y., Takahashi S., Suda M., Higashino K. Xylitol-induced increase in the concentration of oxypurines and its mechanism. Int J Clin Pharmacol Ther 1995, 33(6):360-365.
90. Niewoehner C.B., Gilboe D.P., Nuttall F.Q. Metabolic effects of oral glucose in the liver of fasted rats. Am J Physiol 1984, 247(4 Pt 1):E505-E512.
91. Mercader J., Gomez-Angelats M., del Santo B., Casado F.J., Felipe A., Pastor-Anglada M. Nucleoside uptake in rat liver parenchymal cells. Biochem J 1996, 317(Pt 3):835-842.
92. Martin D.S., Stolfi R.L., Sawyer R.C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 1989, 24(1):9-14.
93. Gomez-Angelats M., del Santo B., Mercader J., et al. Hormonal regulation of concentrative nucleoside transport in liver parenchymal cells. Biochem J 1996, 313(Pt 3):915-920.
94. Brosh S., Boer P., Sperling O., Zoref-Shani E. Elevated UTP and CTP content in cultured neurons from HPRT-deficient transgenic mice. J Mol Neurosci 2000, 14(1-2):87-91.
95. Alonso E., Rubio V. Orotic aciduria due to arginine deprivation: changes in the levels of carbamoyl phosphate and of other urea cycle intermediates in mouse liver. J Nutr 1989, 119(8):1188-1195.
96. Natale P.J., Tremblay G.C. Studies on the availability of intramitochondrial carbamoylphosphate for utilization in extramitochondrial reactions in rat liver. Arch Biochem Biophys 1974, 162(2):357-368.
97. Zaragozá R., Renau-Piqueras J., Portolés M., Hernández-Yago J., Jordá A., Grisolía S. Rats fed prolonged high protein diets show an increase in nitrogen metabolism and liver megamitochondria. Arch Biochem Biophys 1987, 258(2):426-435.
98. Jordá A., Zaragozá R., Portolés M., Báguena-Cervellera R., Renau-Piqueras J. Long-term high-protein diet induces biochemical and ultrastructural changes in rat liver mitochondria. Arch Biochem Biophys 1988, 265(2):241-248.
99. Chikenji T., Asai T., Tatibana M. Protein-diet-induced elevation of 5-phosphoribosyl 1-diphosphate concentrations in mouse liver associated with increased syntheses of various nucleotides and the possible involvement of glucagon. Biochim Biophys Acta 1984, 802(2):274-281.
100. Lalanne M., Henderson J.F. Effects of hormones and drugs on phosphoribosyl pyrophosphate concentrations in mouse liver. Can J Biochem 1975, 53(3):394-399.
101. Sand T.E., Thoresen G.H., Refsnes M., Christoffersen T. Growth-regulatory effects of glucagon, insulin, and epidermal growth factor in cultured hepatocytes. Temporal aspects and evidence for bidirectional control by cyclic AMP. Dig Dis Sci 1992, 37(1):84-92.
102. Branum G.D., Bowers B.A., Watters C.R., et al. Biliary response to glucagon in humans. Ann Surg 1991, 213(4):335-340.
103. Boer P., Mamet R., Sperling O. Acceleration of purine synthesis in mouse liver by glycogenolytic hormones. Biochem Med Metab Biol 1991, 46(2):185-195.
104. Moseley R.H., Jarose S., Permoad P. Adenosine transport in rat liver plasma membrane vesicles. Am J Physiol 1991, 261(5 Pt 1):G716-G722.
105. Ruiz-Montasell B., Javier Casado F., Felipe A., Pastor-Anglada M. Uridine transport in basolateral plasma membrane vesicles from rat liver. J Membr Biol 1992, 128(3):227-233.
106. Che M., Nishida T., Gatmaitan Z., Arias I.M. A nucleoside transporter is functionally linked to ectonucleotidases in rat liver canalicular membrane. J Biol Chem 1992, 267(14):9684-9688.
107. Ruiz-Montasell B., Martinez-Mas J.V., Enrich C., Casado F.J., Felipe A., Pastor-Anglada M. Early induction of Na(+)-dependent uridine uptake in the regenerating rat liver. FEBS Lett 1993, 329(1-2):189-193.
108. Darnowski J.W., Holdridge C., Handschumacher R.E. Concentrative uridine transport by murine splenocytes: kinetics, substrate specificity, and sodium dependency. Cancer Res 1987, 47(10):2614-2619.
109. Cohen J.L., Vinik A., Faller J., Fox I.H. Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production. J Clin Invest 1985, 75(1):251-257.
110. Quesada I., Tudurí E., Ripoll C., Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 2008, 199(1):5-19.
111. Pipeleers D.G., Schuit F.C., Van Schravendijk C.F., Van de Winkel M. Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology 1985 Sep, 117(3):817-823.
112. Haugaard E.S., Frantz K.B., Haugaard N. Effect of uridine on cellular UTP and glycogen synthesis in skeletal muscle: stimulation of UTP formation by insulin. Proc Natl Acad Sci U S A 1977 Jun, 74(6):2339-2342.
113. Rossi Fanelli F., Cangiano C., Capocaccia L., et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut 1986, 27(Suppl. 1):111-115.
114. Miwa Y., Kato M., Moriwaki H., et al. Effects of branched-chain amino acid infusion on protein metabolism in rats with acute hepatic failure. Hepatology 1995, 22(1):291-296.
115. Schwalb H., Kushnir T., Navon G., Yaroslavsky E., Borman J.B., Uretzky G. The protective effect of enriched branched chain amino acid formulation in the ischemic heart: a phosphorous-31 nuclear magnetic resonance study. J Mol Cell Cardiol 1987, 19(10):991-998.
116. Yoneda T., Yoshikawa M., Tsukaguchi K., et al. Supplementary nutrition therapy is effective in patients with chronic obstructive pulmonary disease. Nihon Kyobu Shikkan Gakkai Zasshi 1992, 30(10):1807-1813. [Japanese].
117. Blackburn G.L., Etter G., Mackenzie T. Criteria for choosing amino acid therapy in acute renal failure. Am J Clin Nutr 1978, 31(10):1841-1853.
118. Imai S., Otorii T., Takeda K., Katano Y., Horii D. Effects of cyclic AMP and dibutyryl cyclic AMP on the heart and coronary circulation. Jpn J Pharmacol 1974, 24(4):499-510.
119. Miyagi Y., Sasayama S., Nakajima H., Fujita M., Asanoi H. Comparative hemodynamic effects of intravenous dobutamine and dibutyryl cyclic AMP, a new inotropic agent, in severe congestive heart failure. J Cardiovasc Pharmacol 1990, 15(1):138-143.
120. Suemori I. Experimental study of dibutyryl cyclic AMP; its metabolic effects observed in anesthetized human subjects. Tohoku J Exp Med 1975, 117(2):111-118.
121. Gill G.V., Prudhoe K., Cook D.B., Latner A.L. Effect of surgical trauma on plasma concentrations of cyclic AMP and cortisol. Br J Surg 1975, 62(6):441-443.
122. Ogawa K., Shiozu H., Mizuno K., Ban M., Ito T., Satake T. Increased plasma cyclic nucleotide concentrations in congestive heart failure. Br Heart J 1984, 52(5):524-529.
123. Marumo F., Sakai T., Shirataka M. A multivariate factor analysis of the high plasma concentration of cyclic AMP in patients with chronic renal failure. Int J Artif Organs 1980, 3(1):18-22.
124. Fox R.M., Royse-Smith D., O'Sullivan W.J. Orotidinuria induced by allopurinol. Science 1970, 168(933):861-862.
125. Grobner W., Kelley W.N. Effect of allopurinol and its metabolic derivatives on the configuration of human orotate phosphoribosyltransferase and orotidine 5'-phosphate decarboxylase. Biochem Pharmacol 1975, 24(3):379-384.
126. Kelley W.N., Beardmore T.D., Fox I.H., Meade J.C. Effect of allopurinol and oxipurinol on pyrimidine synthesis in cultured human fibroblasts. Biochem Pharmacol 1971, 20(7):1471-1478.